| Title |
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
|
|---|---|
| Published in |
Investigational New Drugs, April 2019
|
| DOI | 10.1007/s10637-019-00768-6 |
| Pubmed ID | |
| Authors |
Jeffrey P. Sharman, Jennifer J. Wheler, Lawrence Einhorn, Afshin Dowlati, Geoffrey I. Shapiro, John Hilton, John M. Burke, Tanya Siddiqi, Nancy Whiting, Shadia I. Jalal |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 27 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 19% |
| Researcher | 4 | 15% |
| Student > Master | 4 | 15% |
| Student > Bachelor | 4 | 15% |
| Lecturer | 2 | 7% |
| Other | 3 | 11% |
| Unknown | 5 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 48% |
| Biochemistry, Genetics and Molecular Biology | 4 | 15% |
| Nursing and Health Professions | 2 | 7% |
| Unspecified | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 5 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 April 2019.
All research outputs
#15,569,433
of 23,142,049 outputs
Outputs from Investigational New Drugs
#777
of 1,178 outputs
Outputs of similar age
#199,084
of 319,132 outputs
Outputs of similar age from Investigational New Drugs
#10
of 21 outputs
Altmetric has tracked 23,142,049 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,178 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 319,132 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.